BACARDI-LIMITED
16.12.2020 08:02:14 CET | Business Wire | Press release
Bacardi Limited, the world’s largest family-owned spirits company, is launching a new ‘mindful drinking’ campaign this January, designed to help retailers, bars and e-commerce partners tap into a sales opportunity worth a predicted $500m RSV by the end of 2024iii .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215006215/en/
Mindful drinking - the practice of being aware of why, how much and what alcohol we drink - is a cultural movement which has become incredibly popular this year. The concept covers everything from replacing alcohol with alcohol-free spirits, to enjoying longer, low alcohol drinks, as well as taking the time to ‘sip and savour’ cocktails made with the finest, natural ingredients.
This idea of moderation without settling for second-best continues to gain traction across the world, and nowhere more so than in Western Europe. The lockdowns and restrictions of 2020 have only accelerated its growth:
- +30% and +25% more Google searches are for non-alcoholic beverages in the UK and Germany respectively, compared to this time last year
- In both countries, Google searches for “Aperitivo” saw a dramatic rise from March 2020 as people began researching NoLo cocktails to enjoy at homeiv
Brenda Fiala, Global VP, Strategic Insights & Analytics for Bacardi , casts a light on this growing drinks trend: “What really stands out in our insights is just how huge mindful drinking has become in Western Europe this year (compared to last year). It is becoming the ‘NoLo capital of the world’. As lockdown impacted our lives and routines, not only did people begin to seek out lower ABV cocktails, they also began enjoying cocktails a little earlier than usual and began experimenting with longer drinks and alcohol-free options. That meant mindful drinking really took off and it’s here to stay.”
Over a third (36%) of consumers across the UK, France and Germany planning on enjoying cocktails more mindfully during Decemberv
- Partipation in a ‘Dry-ish January’ is set to be at its highest ever – almost half (48%) of consumers surveyed in the UKvi and a quarter (24%) of those asked in Germany, plan to take partvii
With its successful portfolio of NoLo drinks, the family-owned sprits company has been ahead of the curve on the mindful drinking trend, and this new ‘Less is More’ campaign demonstrates an even bigger focus and investment in the category’s future. It will drive awareness of the company’s mindful drinking line-up of premium drinks, including recently launched MARTINI Non-Alcoholic Aperitivo, as well as MARTINI Fiero vermouth and ST-GERMAIN® elderflower liqueur.
Marine Rozenfeld, Innovation Development Lead for Bacardi for Western Europe, Australia & New Zealand , comments: “We know people are stepping up their cocktail game with premium spirits, putting quality over quantity, and at the same time, are intrigued by the explosion of new alcohol-free spirits available to choose from. Now it’s about taking them further on the journey of exploration. From MARTINI Non-Alcoholic cocktails , to longer drinks like the ST-GERMAIN Spritz and the MARTINI Fiero & Tonic, we want to help give people the tools and know-how they need to drink mindfully. Our message is very simple - ‘Less is More ’ - more taste, more experience.”
The new Bacardi marketing initiative has two key focuses – visibility and education – aiming to signpost “NoLo” options for cocktail-lovers, bartenders and store owners, in a way that’s both engaging and easy-to-understand.
Bacardi will be:
- deploying menu cards and editable templates to bars
- leaflets and stand-out POS displays in retail
- launching dedicated ‘Less is More ’ Amazon gift stores in UK, Germany and Spain to inspire at-home bartenders with recipes and interactive content
- using social media to drive awareness for MARTINI Non-Alcoholic Aperitivo in selected markets
- hosting samplings across retail and when they can reopen, in bars
Bartenders are getting excited by the opportunities to create amazing mindful cocktails too. As Bacardi continues to support the bar industry through its #RaiseYourSpirits initiative, its education program on how to create cocktails for mindful drinkers, is another way in which the company is helping bar owners maximise sales by tapping into this trend once they reopen.
For those looking to drink mindfully during the festive season, to participate in Dry January or for gifting ideas for mindful drinkers, Bacardi has Gift Stores on Amazon in the UK, France, Germany, Spain and Italy where they can shop for fantastic NoLo premium spirits including a MARTINI Non-Alcoholic Aperitivo Vibrante and Floreale Dual Set (2 x 75cl).
NOTES TO EDITORS
Always drink responsibly
For the facts: Drinkaware.co.uk
About Bacardi
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .
ALL MARKS APPEARING ON THE BACARDI GROUP PRODUCTS SHOWN OR MENTIONED ARE TRADEMARKS OF BACARDI & COMPANY LIMITED OR OF OTHER SUBSIDIARIES OF BACARDI LIMITED.
_____________________
i
Bacardi predicted value of the NoLo spirits category ($) in Western Europe by 2024, based on IWSR predictions. All channels.
ii
Indicative results based on consumer research conducted in the UK, France and Germany. 50% UK participants, 34% French participants and 23.5% German participants said they plan to drinking more mindfully during the festive season
iii
Bacardi predicted value of the NoLo spirits category ($) in Western Europe by 2024, based on IWSR predictions. All channels.
iv
Independent Google trends data
v
Indicative results based on consumer research conducted in the UK, France and Germany. 50% UK participants, 34% French participants and 23.5% German participants said they plan to drinking more mindfully during the festive season.
vi
The research of 1,000 UK respondents aged 18-55 was conducted via Perspectus Global during October 2020.
vii
In the period from 19-20.11.2020, the market and opinion research company Civey asked more than 3,800 people in Germany who drink alcohol about their consumption of alcohol during the pandemic, the Christmas holidays and the Dry January.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215006215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
